This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.

Percutaneous transseptal mitral valve replacement (TMVR) with the SAPIEN M3 System significantly reduced mitral regurgitation (MR) severity, improved functional status and quality of life, and achieved low mortality and heart failure hospitalization rates at one year, according to results from the ENCIRCLE trial presented by Dr. David Daniels, Dr. Mayra Guerrero, and Dr. John Webb on behalf of the ENCIRCLE investigators at TCT 2025.

The ENCIRCLE trial is the first pivotal study to evaluate outcomes of a fully percutaneous, transseptal TMVR system in patients with symptomatic MR who are not suitable candidates for surgery or other commercially available transcatheter

See Full Page